Supplementary Figure 1 (related to Fig. 1 ): Nr2f6 loss results in increased GC response to SRBC. Nr2f6 +/+ or Nr2f6 -/mice were immunized with 5x10 8 sheep red blood cells or given PBS as a negative control. On day 7 postimmunization, spleens were harvested and stained for (A) Tfh cells (CD4 + CXCR5 + PD-1 + ) frequency of all mice is shown in the right panel. (B) GC B cells (IgD neg B220 + Fas + GL7 + ) and (C) plasma cells (B220 int CD45 + CD138 + ) along with total frequency of each population to the right. Data shown are from two independent experiments with n≥6. Error bars represent SD, an asterisk (*) indicates statistically significant differences calculated using Student's t-test. A p-value of < 0.05 was considered statistically significant. * p <0.05; ** p <0.01; *** p <0.001. Fig. 1 ): Nr2f6-deficiency does not alter proliferation or total Treg cell number after OVA immunization. Nr2f6 +/+ or Nr2f6 -/mice were immunized with OVA precipitated in 10% alum 4 days later (A) Tfh cells (CD4 + CXCR5 + PD-1 + ) were co-stained for Ki67 frequency. (B) Frequency of BrdU incorporation on day 10 after 7-12 hours pulse labelling of mice was performed on Tfh (p=0.056), GC B (IgD neg B220 + Fas + GL7 + ) (p=0.0506) and plasma cells (B220 int CD45 + CD138 + ). (C) Representative day 10 staining of Treg cells (CXCR5-PD-1-CD4+ FoxP3+) and total Treg numbers. Data shown are from at least two separate experiments with n≥5. Middle bar represents average for the data set. Error bars represent SD, an asterisk (*) indicates statistically significant differences calculated using two-tailed Student's t-test. 
